Elevating Drug Development.

Every Step of the Way

About Scinai Immunotherapeutics
nasdaq: scni

Scinai is a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bio-services business unit.

View our company video

Inflammatory & IMMUNOLOGY
Therapeutics Pipeline

Scinai is focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases.

Our Alpaca-derived nanosized antibodies (nanoAbs), also known as VHH-antibodies, address diseases with large unmet medical needs and attractive commercial opportunities, such as psoriasis and asthma.

Diverse drug platform

Proven target molecules
& mechanism of action

Addressing large markets with unmet needs

Saving costs & improving patient compliance

EXPLANATORY WEBINAR

DEVELOPED IN collaboration with WORLD LEADERS IN NANOAB
discovery & OPTIMIZATION

Professor Dr.
Dirk Görlich

Professor & Director at Max Planck Institute for Multidisciplinary Sciences

2024 Louis-Jeantet
Prize & 2022 WLA Prize

Professor Dr. Matthias Dobbelstein

Max Planck Institute Fellow, Professor and Department Head at the University of Göttingen

Scinai’s NanoAbs are developed in collaboration with the world-renowned Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen, Germany.
Our scientific partners are leaders in designing and optimizing NanoAbs.

Corporate presentation

Investors information

Scinai CDMO Bio-Services

MOLECULE & CLONE SELECTION

LAB SCALE

CMC

PREPARATION FOR CLINICAL TRIAL

PRE-CLINICAL

TECH TRANSFER

REGULATORY

CLINICAL TRIALS

Our boutique biologics CDMO is designed to support biotech innovators through every stage of drug development - from early research to Phase 3 manufacturing.

Backed by over 20 years of experience and a state-of-the-art cGMP facility, we deliver flexible, agile, and cost-effective solutions that combine scientific innovation with process excellence for reliable, high-quality product delivery.

Comprehensive Biologics Development & Manufacturing Services

Scinai BioServices offers end-to-end CDMO solutions supporting biologics development from early-stage research through late-phase manufacturing.

cGMP Manufacturing

Our high-end manufacturing suites are designed to meet FDA and EMA cGMP standards and have successfully passed European QP (EMA) and Israeli MoH audits for Phase 3 clinical trial production.

Analytical
Methods
Development

Our experienced team of scientists utilizes advanced analytical technologies to ensure precise and reliable product characterization. We provide comprehensive analytical method development for in-process control, release testing, and detailed analysis of recombinant proteins.

Process Development
& Scale-Up

With extensive expertise in recombinant protein development, Scinai delivers cost-effective, flexible, and scalable process development and scale-up solutions. Our experts guide clients through each stage of research and development, helping to minimize risks and accelerate progress toward clinical success.